• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypertension-Pipeline Review H1 2017

    Hypertension-Pipeline Review H1 2017

    • Report Code ID: RW0001834389
    • Category Pharmaceuticals
    • No. of Pages 547
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Hypertension - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H1 2017, provides an overview of the Hypertension (Cardiovascular) pipeline landscape.

    Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 35, 35, 31, 89, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 11 molecules, respectively.

    Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 7
    Hypertension - Overview 8
    Hypertension - Therapeutics Development 9
    Hypertension - Therapeutics Assessment 36
    Hypertension - Companies Involved in Therapeutics Development 54
    Hypertension - Drug Profiles 111
    Hypertension - Dormant Projects 497
    Hypertension - Discontinued Products 511
    Hypertension - Product Development Milestones 513
    Appendix 522

    List of Tables

    Number of Products under Development for Hypertension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hypertension - Pipeline by A1M Pharma AB, H1 2017
    Hypertension - Pipeline by Actelion Ltd, H1 2017
    Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by AnGes MG Inc, H1 2017
    Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017
    Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017
    Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Bayer AG, H1 2017
    Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017
    Hypertension - Pipeline by Biolab Farmaceutica Ltda, H1 2017
    Hypertension - Pipeline by BioRestorative Therapies Inc, H1 2017
    Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Hypertension - Pipeline by Camurus AB, H1 2017
    Hypertension - Pipeline by Capricor Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Celsion Corp, H1 2017
    Hypertension - Pipeline by Celtaxsys Inc, H1 2017
    Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017
    Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Hypertension - Pipeline by CJ HealthCare Corp, H1 2017
    Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Corion Biotech Srl, H1 2017
    Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Cytokinetics Inc, H1 2017
    Hypertension - Pipeline by Daewoong Co Ltd, H1 2017
    Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Hypertension - Pipeline by DiaMedica Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Eli Lilly and Company, H1 2017
    Hypertension - Pipeline by Esperion Therapeutics Inc, H1 2017
    Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Hypertension - Pipeline by Ferring International Center SA, H1 2017
    Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Gemphire Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Gilead Sciences Inc, H1 2017
    Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2017
    Hypertension - Pipeline by H. Lundbeck A/S, H1 2017
    Hypertension - Pipeline by HanAll Biopharma Co Ltd, H1 2017
    Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
    Hypertension - Pipeline by HitGen LTD, H1 2017
    Hypertension - Pipeline by Innopharmax Inc, H1 2017
    Hypertension - Pipeline by Insmed Inc, H1 2017
    Hypertension - Pipeline by Insys Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Hypertension - Pipeline by Johnson & Johnson, H1 2017
    Hypertension - Pipeline by JW Pharmaceutical Corp, H1 2017
    Hypertension - Pipeline by Kowa Company Ltd, H1 2017
    Hypertension - Pipeline by Leading BioSciences Inc, H1 2017
    Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
    Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2017
    Hypertension - Pipeline by LinXis BV, H1 2017
    Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017
    Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
    Hypertension - Pipeline by MannKind Corp, H1 2017
    Hypertension - Pipeline by Marina Biotech Inc, H1 2017
    Hypertension - Pipeline by Merck & Co Inc, H1 2017
    Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017
    Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
    Hypertension - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2017
    Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
    Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017
    Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
    Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Novartis AG, H1 2017
    Hypertension - Pipeline by Noxamet Ltd, H1 2017
    Hypertension - Pipeline by Omeros Corp, H1 2017
    Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Pfizer Inc, H1 2017
    Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Polyphor Ltd, H1 2017
    Hypertension - Pipeline by Pulmokine Inc, H1 2017
    Hypertension - Pipeline by Quantum Genomics SA, H1 2017
    Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by RedHill Biopharma Ltd, H1 2017
    Hypertension - Pipeline by Relypsa Inc, H1 2017
    Hypertension - Pipeline by Renova Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
    Hypertension - Pipeline by rEVO Biologics Inc, H1 2017
    Hypertension - Pipeline by Rottapharm Biotech Srl, H1 2017
    Hypertension - Pipeline by Sanofi, H1 2017
    Hypertension - Pipeline by Savara Inc, H1 2017
    Hypertension - Pipeline by Serodus ASA, H1 2017
    Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
    Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017
    Hypertension - Pipeline by Simcere Pharmaceutical Group, H1 2017
    Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017
    Hypertension - Pipeline by Suda Ltd, H1 2017
    Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
    Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Hypertension - Pipeline by The Medicines Company, H1 2017
    Hypertension - Pipeline by Theravance Biopharma Inc, H1 2017
    Hypertension - Pipeline by Toray Industries Inc, H1 2017
    Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017
    Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H1 2017
    Hypertension - Pipeline by United Therapeutics Corp, H1 2017
    Hypertension - Pipeline by Vascular BioSciences, H1 2017
    Hypertension - Pipeline by Vectura Group Plc, H1 2017
    Hypertension - Pipeline by VG Life Sciences Inc, H1 2017
    Hypertension - Pipeline by Vicore Pharma AB, H1 2017
    Hypertension - Pipeline by Vivus Inc, H1 2017
    Hypertension - Pipeline by XORTX Pharma Corp, H1 2017
    Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
    Hypertension - Pipeline by Yuhan Corp, H1 2017
    Hypertension - Dormant Projects, H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..7) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..8) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..9) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..10) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..11) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..12) , H1 2017
    Hypertension - Dormant Projects, H1 2017 (Contd..13) , H1 2017
    Hypertension - Discontinued Products, H1 2017
    Hypertension - Discontinued Products, H1 2017 (Contd..1) , H1 2017

    List of Figures

    Number of Products under Development for Hypertension, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    A1M Pharma AB
    Actelion Ltd
    Alnylam Pharmaceuticals Inc
    Anacor Pharmaceuticals Inc
    AnGes MG Inc
    Arena Pharmaceuticals Inc
    Ascendis Pharma A/S
    Asklepion Pharmaceuticals LLC
    AVEO Pharmaceuticals Inc
    Bayer AG
    Bial - Portela & Ca SA
    Biolab Farmaceutica Ltda
    BioRestorative Therapies Inc
    Boryung Pharmaceutical Co Ltd
    Bristol-Myers Squibb Company
    Camurus AB
    Capricor Therapeutics Inc
    Celsion Corp
    Celtaxsys Inc
    Chiesi Farmaceutici SpA
    Chong Kun Dang Pharmaceutical Corp
    CJ HealthCare Corp
    Conatus Pharmaceuticals Inc
    Corion Biotech Srl
    Cumberland Pharmaceuticals Inc
    Cytokinetics Inc
    Daewoong Co Ltd
    Daewoong Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    DiaMedica Therapeutics Inc
    Eli Lilly and Company
    Esperion Therapeutics Inc
    F. Hoffmann-La Roche Ltd
    Ferring International Center SA
    Galectin Therapeutics Inc
    Gemphire Therapeutics Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    H. Lundbeck A/S
    HanAll Biopharma Co Ltd
    Hanmi Pharmaceuticals Co Ltd
    HitGen LTD
    Innopharmax Inc
    Insmed Inc
    Insys Therapeutics Inc
    Ionis Pharmaceuticals Inc
    Ironwood Pharmaceuticals Inc
    Jeil Pharmaceutical Co Ltd
    Johnson & Johnson
    JW Pharmaceutical Corp
    Kowa Company Ltd
    Leading BioSciences Inc
    Lee's Pharmaceutical Holdings Ltd
    Les Laboratoires Servier SAS
    LinXis BV
    Liquidia Technologies Inc
    Lotus Pharmaceutical Co Ltd
    MannKind Corp
    Marina Biotech Inc
    Merck & Co Inc
    Mezzion Pharma Co Ltd
    Mitsubishi Tanabe Pharma Corp
    Nanoform Cardiovascular Therapeutics Ltd
    Neurim Pharmaceuticals Ltd
    Nippon Kayaku Co Ltd
    Nippon Shinyaku Co Ltd
    Northern Therapeutics Inc
    Novartis AG
    Noxamet Ltd
    Omeros Corp
    Peloton Therapeutics Inc
    Pfizer Inc
    PhaseBio Pharmaceuticals Inc
    Pluristem Therapeutics Inc
    Polyphor Ltd
    Pulmokine Inc
    Quantum Genomics SA
    Reata Pharmaceuticals Inc
    RedHill Biopharma Ltd
    Relypsa Inc
    Renova Therapeutics Inc
    Respira Therapeutics Inc
    Reviva Pharmaceuticals Inc
    rEVO Biologics Inc
    Rottapharm Biotech Srl
    Sanofi
    Savara Inc
    Serodus ASA
    Shanghai Pharmaceutical Co Ltd
    Silence Therapeutics Plc
    Simcere Pharmaceutical Group
    SteadyMed Therapeutics Inc
    Suda Ltd
    Sumitomo Dainippon Pharma Co Ltd
    Sun Pharma Advanced Research Company Ltd
    Takeda Pharmaceutical Company Ltd
    The Medicines Company
    Theravance Biopharma Inc
    Toray Industries Inc
    Torrent Pharmaceuticals Ltd
    TSH Biopharm Corporation Ltd
    United Therapeutics Corp
    Vascular BioSciences
    Vectura Group Plc
    VG Life Sciences Inc
    Vicore Pharma AB
    Vivus Inc
    XORTX Pharma Corp
    XuanZhu Pharma Co Ltd
    Yuhan Corp

    Request for Sample

    Report Url https://www.reportsweb.com//hypertension-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//hypertension-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//hypertension-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments